Clinical trials
Phase 2 Lung Neoplasms trials in the United Kingdom
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
37 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2003 | 3 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 3 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 26 |
| Recruiting | 3 |
| Terminated | 3 |
| Active, not recruiting | 2 |
| Unknown status | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 5 |
| European Organisation for Research and Treatment of Cancer - EORTC | 3 |
| Boehringer Ingelheim | 2 |
| Eli Lilly and Company | 2 |
| Incyte Corporation | 2 |
| Pfizer | 2 |
| Agenus Inc. | 1 |
| Apollomics Inc. | 1 |
| AstraZeneca | 1 |
| Celgene | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lung Neoplasms | 37 |
| Carcinoma, Non-Small-Cell Lung | 26 |
| Adenocarcinoma of Lung | 4 |
| Pancreatic Neoplasms | 4 |
| Head and Neck Neoplasms | 3 |
| Lung Diseases | 3 |
| Neoplasm Metastasis | 3 |
| Adenocarcinoma | 2 |
| Brain Neoplasms | 2 |
| Bronchial Neoplasms | 2 |
Trials
Showing 1 to 25 of 37. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.